Premium
P3‐427: Nerve growth factor treatment in Alzheimer's disease: Effects on EEG
Author(s) -
Eyjolfsdottir Helga,
Jonhagen Maria Eriksdotter,
Almqvist Owe,
Almqvist Per,
Kadir Ahmadul,
Lind Göran,
Linderoth Bengt,
Wahlberg Lars,
Seiger Åke,
Jelic Vesna
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.05.1871
Subject(s) - basal forebrain , electroencephalography , nerve growth factor , medicine , tolerability , cholinergic neuron , cholinergic , anesthesia , neuroscience , endocrinology , cardiology , psychology , receptor , adverse effect
to reduce the risks for occurrence or re-occurrence of cerebrovascular events as well as reducing other vascular risks, such as hypertension, diabetes, smoking, physical inactivity, and others. Treatments for MD usually involve a combination of both AD and VD treatments. Similarly, research also is focused on either AD or VD and notMD.Methods:We examined themechanisms of action of omega-3 fatty acids in the contexts of both AD andVD in order to determine if the use of omega-3 scould be applicable in regards to MD.Results:Omega-3 fatty acids may be beneficial to persons withMD by potentially reducing neuroinflammation associated with both AD and VD symptoms. Conclusions: There is very little research in regards to MD. Since there are common threads between AD and VD, such as neuroinflammation, therapies that target these common threads, such as omega-3 supplementation should be explored. Since many persons with dementia exhibit both AD and VD pathology, such treatments would be extremely beneficial if demonstrated to be efficacious.